Photo:
utswmed.org
Mar 5, 2026, 15:51
Samer Al Hadidi: Cytopenias and Infection Risk With BCMA-Directed Bispecific Antibodies
Samer Al Hadidi, Associate Professor at UT Southwestern Medical Center, shared a post on LinkedIn:
“The Overlooked Burden of Cytopenias With BCMA-Directed Bispecific Antibodies
Hematologic toxicity is underappreciated:
- 87% of pts: grade 3-4 lymphopenia
- 55% grade 3-4 neutropenia (65% with teclistamab)
- 74% required dose interruptions
- 54.5% needed G-CSF
This is likely one of the important causes of higher grade infections with those agents.
We need to think about preventive strategies given the high efficacy of those agents.”
Stay updated with Hemostasis Today.
-
Sep 12, 2026, 07:02Melissa Hollo: Pre-Operative Anemia – An Underrecognized Challenge in Surgical Care
-
Sep 12, 2026, 06:57Klaus Metzeler: ESH 2026 MDS Conference – Connecting Experts Across Hematology
-
Sep 12, 2026, 06:40Lakmali Silva: Fibrinolysis and Its Role in Hematopoietic Recovery After Chemotherapy
-
Sep 12, 2026, 06:30Alexander Misono: Improving DVT Diagnosis and Care Through Venous Duplex Ultrasound
-
Sep 12, 2026, 06:06Simone Cesaro: GNE-Related Thrombocytopenia – New Findings
-
Sep 12, 2026, 04:11Jyotishbhai Patel: Why India Needs Universal Newborn Screening for Sickle Cell and Thalassemia
-
Sep 12, 2026, 04:04Oliver Schlager: New ESC and ESVM Clinical Consensus on Lipid-Lowering Therapy in VTE
-
Sep 12, 2026, 03:54Toby Richards: Representing IronLife at Parliament on Anaemia and Iron Deficiency
-
Sep 12, 2026, 03:50Saleh Shamse Basha: When ‘Low Protein S’ Isn’t Necessarily Low